Skip to main content
SpringerLink
Log in

Schwerpunkt "Zelluläre Therapien"

CAR-T-Zell-Therapien in der Hämatoonkologie: Update und Ausblick

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Wang M et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331-42

  2. Bücklein V et al. CD19 CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma - The Munich Real Life Experience. EHA. 2020;Abstr EP1511

  3. Rejeski K et al. Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies. ASH. 2020;Abstr 1446

  4. Schuster SJ et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56

  5. Logue JM et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma- Haematologica. 2020; https://doi.org/ 10.3324/haematol.2019.238634

  6. Fried S et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643-50

  7. Jain T et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776-87

  8. Cordeiro A et al. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transplant. 2020;26(1):26-33

  9. Nahas GR et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61(4)940-3

Download references

Author information

Authors and Affiliations

  1. Med. Klinik u. Poliklinik III, Klinikum der Univ. München, Marchioninistr. 15, 81377, München, Deutschland

    Marion Subklewe

Authors
  1. Marion Subklewe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Subklewe, M. CAR-T-Zell-Therapien in der Hämatoonkologie: Update und Ausblick . InFo Hämatol Onkol 24, 16–19 (2021). https://doi.org/10.1007/s15004-021-8647-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8647-1

Search

Navigation